Holen Sie sich die Stockscreener-App
5.85
31.71%
-2.68
Schlusskurs vom Vortag:
$8.53
Offen:
$6.45
24-Stunden-Volumen:
7.75M
Relative Volume:
18.87
Marktkapitalisierung:
$291.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-24.94%
1M Leistung:
-0.60%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.27
$6.80
1-Wochen-Bereich:
$5.27
$8.5498
52-Wochen-Spanne:
$5.27
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Firmenname
Helus Pharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
5.837 | 425.60M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.80 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.85 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.34 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.15 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Eingeleitet | Jefferies | Buy |
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Helus Pharma Inc Aktie (HELP) Neueste Nachrichten
Helus Pharma’s top-line Phase II data signal detection study for HLP004 - The Pharma Letter
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Benzinga
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Investing News Network
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
Helus Pharma (HELP) Shares Drop Despite Positive Phase 2 Trial Results - GuruFocus
Helus Pharma (HELP) Reports Positive Phase 2 Study Results for A - GuruFocus
Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety - TipRanks
Helus stock falls on data for anxiety therapy (HELP:NASDAQ) - Seeking Alpha
Helus Pharma Announces Topline Results In Phase 2 Signal Detection Study For Hlp004 In Patients With Generalized Anxiety Disorder - TradingView
Experimental anxiety drug helps 67% of hard-to-treat patients - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Helus Pharma (HELP) Price Target Raised by HC Wainwright & Co. | - GuruFocus
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - The AI Journal
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - The Malaysian Reserve
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments - Baystreet.ca
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors - Investing.com India
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan
Helus Pharma appoints former Pfizer chief medical officer to board of directors - marketscreener.com
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee - Toronto Star
Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise - Finviz
Cybin (Helus Pharma) Names Veteran Pharma Executive Michael Cola as CEO to Drive CNS Growth - The Globe and Mail
HELP Stock Price and Chart — NEO:HELP - TradingView
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers - Finviz
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth Drivers - Yahoo Finance
Industry veteran Michael Cola named Cybin (CYBN) chief executive - Stock Titan
Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA - BioPharma Dive
Helus Pharma reports positive phase 2a trial results for depression drug - Investing.com Australia
Cybin stock surges after positive Phase 2a trial results for depression drug - Investing.com
HELP SEC FilingsCybin Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cybin Inc.Common Stock (Nasdaq:HELP) Stock Quote - The Chronicle-Journal
HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’ - Stocktwits
Helus gains on published data for psychedelic drug (HELP) - Seeking Alpha
Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - Investing News Network
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - Toronto Star
Helus Pharma To Report Phase 2 Data For HLP004 In Generalized Anxiety Disorder This Quarter - Nasdaq
Helus Pharma (HELP) Advances Neuro Portfolio with Robust Financi - GuruFocus
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Investing News Network
Cybin (Helus Pharma) Posts Higher Assets, Equity and Losses in Q3 FY2026 SEC Filing - TipRanks
Helus Pharma (NASDAQ: HELP) widens loss while sharply increasing cash - Stock Titan
Helus Pharma appoints Michael Cola as CEO - The Pharma Letter
HELUS PHARMA NAMES MICHAEL COLA AS CEO FOR NEXT PHASE OF GROWTH - Bernama
Helus Pharma Names Michael Cola As CEO For Next Phase Of GrowthBERNAMA - BERNAMA - Malaysian National News Agency
Finanzdaten der Helus Pharma Inc-Aktie (HELP)
Es liegen keine Finanzdaten für Helus Pharma Inc (HELP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):